← Russell 3000 cross-section

WST WEST PHARMACEUTICAL SERVICES INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-23, not restated
Healthcare

Scale

Market cap
$24.6bn
Revenue TTM
$3.3bn
Net income TTM
$565m
Free cash flow
$437m
Composite score
51.1
Sector rank
#393

Valuation

P / E
43.6
EV / EBITDA
28.3
EV / sales
7.3
FCF yield
1.78%
Earnings yield vs 10-yr
-2.43pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.0%
EBITDA margin
25.9%
ROE
18.9%
ROIC
24.7%
Revenue growth
12.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net Sales The following table presents net sales, consolidated and by reportable segment, for the three and six months ended June 30, 2026 and 2025: Consolidated net sales increased by $105.8 million, or 13.8%, for the three months ended June 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $8.5 million. Excluding foreign currency translation effects, consolidated net sales for the three months ended June 30, 2026 increased by $97.3 million, or 12.7%, as compared to the same period in 2025. …WEST PHARMACEUTICAL SERVICES INC, 10-Q, period ended 2026-06-30, filed 2026-07-23

Read the full passage →